← Back to Search

5-HT3 Receptor Antagonist

1mg AZ010 for Cyclic Vomiting Syndrome

Phase 2
Waitlist Available
Research Sponsored by Alexza Pharmaceuticals, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 24 hours
Awards & highlights

Study Summary

This study is evaluating whether a drug may help reduce the frequency of vomiting in individuals with cyclic vomiting syndrome.

Eligible Conditions
  • Cyclic Vomiting Syndrome

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~24 hours
This trial's timeline: 3 weeks for screening, Varies for treatment, and 24 hours for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
The number of vomiting/retching events in the 2 hours following treatment.
Secondary outcome measures
Number of adverse events as a measure of safety

Trial Design

3Treatment groups
Experimental Treatment
Group I: PlaceboExperimental Treatment1 Intervention
Single orally-inhaled dose
Group II: 3mg AZ010Experimental Treatment1 Intervention
Single orally-inhaled dose
Group III: 1mg AZ010Experimental Treatment1 Intervention
Single orally-inhaled dose
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
1mg AZ010
2021
Completed Phase 2
~160
Staccato Placebo
2007
Completed Phase 2
~400
3mg AZ-010
2019
Completed Phase 2
~220

Find a Location

Who is running the clinical trial?

Alexza Pharmaceuticals, Inc.Lead Sponsor
30 Previous Clinical Trials
12,721 Total Patients Enrolled
Larry Carter, PhDStudy DirectorAlexza Pharmaceuticals, Inc.

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Who else is applying?

What state do they live in?
Georgia
Pennsylvania
Texas
How old are they?
18 - 65
What site did they apply to?
Summit Clinical Studies
Temple University Hospital
Baylor College of Medicine
Other
What portion of applicants met pre-screening criteria?
Met criteria

How responsive is this trial?

Typically responds via
Email
Recent research and studies
clinicaltrials.govStudy
Staccato Granisetron® (AZ 010) for the Treatment of Cyclic Vomiting Syndrome
2021. "Staccato Granisetron® (AZ 010) for the Treatment of Cyclic Vomiting Syndrome". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04645953.
~36 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top